Efzofitimod: a novel anti-inflammatory agent for sarcoidosis

Efzofitimod is a first-in-class biologic immunomodulator based on a naturally occurring splice variant of histidyl-tRNA synthetase (HARS) that binds to neuropilin-2 (NRP2). Preclinical data found high expression of NRP2 in sarcoidosis granulomas. Treatment with efzofitimod reduced the granulomatous inflammation induced by P. acnes in an animal model of sarcoidosis. An ascending dose study of efzofitimod in sarcoidosis with chronic symptomatic pulmonary disease found that treatment with efzofitimod was associated with improved quality of life with a trend towards reduced glucocorticoid use and stable to improved pulmonary function. These studies have led to a large Phase 3 trial of efzofitimod in symptomatic pulmonary sarcoidosis.

[1]  S. Aryal,et al.  Efzofitimod for the Treatment of Pulmonary Sarcoidosis , 2022, Chest.

[2]  Xin Li,et al.  Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China , 2022, Clinical Rheumatology.

[3]  A. Russell,et al.  Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches , 2022, Frontiers in Medicine.

[4]  I. Lundberg,et al.  Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond , 2022, Frontiers in Immunology.

[5]  E. Crouser,et al.  Late Breaking Abstract - Immunomodulatory protein ATYR1923 disrupts an in vitro model of sarcoid granuloma formation , 2021, Sarcoidosis and other granulomatous ILD / DPLD.

[6]  Alexander G. Mathioudakis,et al.  ERS clinical practice guidelines on treatment of sarcoidosis , 2021, European Respiratory Journal.

[7]  R. Baughman,et al.  Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update , 2021, Expert Review of Clinical Pharmacology.

[8]  S. Birring,et al.  Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire (KSQ) in a Multi-center, Prospective Study. , 2020, Annals of the American Thoracic Society.

[9]  S. Crampton,et al.  Neuropilin-2, the Specific Binding Partner to ATYR1923, Is Expressed in Sarcoid Granulomas and Key Immune Cells , 2020 .

[10]  B. Cornils.  synthetases , 2020, Catalysis from A to Z.

[11]  R. Blankstein,et al.  Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[12]  K. Ogilvie,et al.  Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses , 2019, Cellular & Molecular Immunology.

[13]  S. Paz,et al.  ATYR1923 Modulates the Inflammatory Response in Experimental Models of Interstitial Lung Disease , 2019, A101. TRANSLATIONAL STUDIES IN ILD, IPF, AND SARCOIDOSIS.

[14]  M. Hernandez,et al.  Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[15]  Awanish Kumar,et al.  Aminoacyl-tRNA synthetases: Structure, function, and drug discovery. , 2018, International journal of biological macromolecules.

[16]  C. Donatelli,et al.  Toxicity risk from glucocorticoids in sarcoidosis patients. , 2017, Respiratory medicine.

[17]  S. Batra,et al.  Multifaceted Role of Neuropilins in the Immune System: Potential Targets for Immunotherapy , 2017, Front. Immunol..

[18]  C. Francklyn.  Aminoacyl-tRNA synthetases. , 2017, Methods.

[19]  R. Yucel,et al.  The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. , 2015, Respiratory medicine.

[20]  W. Wong,et al.  Human tRNA synthetase catalytic nulls with diverse functions , 2014, Science.

[21]  G. Raghu,et al.  Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis , 2014, European Respiratory Journal.

[22]  A. Burke,et al.  End-stage Sarcoid Lung Disease Is Distinct From Usual Interstitial Pneumonia , 2013, The American journal of surgical pathology.

[23]  J. Verschakelen,et al.  Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. , 2011, Respiratory medicine.

[24]  S. Sone,et al.  Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice , 2011, European Respiratory Journal.

[25]  J. Moss,et al.  Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. , 2009, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[26]  M. Iannuzzi,et al.  Use of fluticasone in acute symptomatic pulmonary sarcoidosis. , 2002, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[27]  Shoji Kudoh,et al.  Quantitative Analysis of Mycobacterial and Propionibacterial DNA in Lymph Nodes of Japanese and European Patients with Sarcoidosis , 2002, Journal of Clinical Microbiology.

[28]  D. H. Gauss,et al.  Histidyl-tRNA Synthetase , 1999, Biological chemistry.

[29]  R. Baughman,et al.  Predictors of Mortality in Pulmonary Sarcoidosis , 2018, Chest.